2nd Edition of Cell & Gene Therapy Conference (CGTWC 2026)
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2nd Edition of Cell & Gene Therapy Conference (CGTWC 2026) — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
2nd Edition of Cell & Gene Therapy Conference (CGTWC 2026)
Event Overview
Date: November 12–14, 2026
Venue: McCormick Place Convention Center, Chicago, Illinois, USA
Event Type: Biotechnology, Pharmaceutical, Medical Research, Clinical Development, Manufacturing, Regulatory Affairs
Estimated Attendance: 4,500+ global attendees including researchers, clinicians, executives, investors, regulatory bodies, and industry partners. Over 200 exhibitors and 150+ speakers expected.
1. Who Attends (Buyers/Attendees)
CGTWC 2026 attracts a specialized audience of decision-makers and key stakeholders in cell and gene therapy development and commercialization. Primary attendee categories include:
- Biopharmaceutical executives (CEO, CTO, CSO, R&D Directors)
- Clinical researchers and principal investigators
- Manufacturing and supply chain leaders
- Regulatory affairs and compliance officers
- Investors and venture capital representatives
- Academic and hospital-based clinicians
- Contract manufacturing organizations (CMOs)
- Technology and service providers (e.g., GMP equipment, vectors, analytics)
2. Location & Attendee Geographic Origin
Show Location: McCormick Place Convention Center, Chicago, Illinois, USA
Attendee Origin: Global audience with strong North American presence (60%+), complemented by European (25%), Asian (10%), and rest-of-world (5%) participants. Key markets include:
- USA (national representation across biotech hubs like Boston, San Francisco, Philadelphia)
- Europe (UK, Germany, France, Netherlands)
- Asia-Pacific (Japan, South Korea, Singapore, China)
- Emerging markets in Latin America and Middle East
Best Geographic Targeting: North America (especially Chicago biotech corridor), EU life sciences clusters, and APAC innovation hubs.
3. Audience Reach
Reach Type: Global with deep North American penetration. This event serves as a nexus for international collaboration in advanced therapies, attracting multinational corporations, startups, academia, and regulatory agencies.
4. Sample Buyer Company Names & Websites
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Moderna Therapeutics | modernatx.com | VP, Cell & Gene Therapy Development | Leader in mRNA platforms expanding into gene therapies; active in clinical development tools |
| 2 | Roche Pharmaceuticals | roche.com | Global Head, Advanced Therapies | Major investor in gene therapy R&D with pipeline assets in hematology and oncology |
| 3 | Lonza Group | lonza.com | Director, Cell & Gene Therapy Manufacturing | Leading CMO with dedicated ATMP (Advanced Therapy Medicinal Products) facilities |
| 4 | Thermo Fisher Scientific | thermofisher.com | Sr. Marketing Manager, Cell Therapy Solutions | Supplies critical equipment and services for cell line development and GMP production |
| 5 | Bluebird Bio | bluebirdbio.com | Chief Medical Officer | Pioneer in gene therapy with approved products for beta-thalassemia and LCA10 |
| 6 | GE Healthcare | gehealthcare.com | Product Manager, Cell Therapy Platforms | Provides end-to-end solutions including bioreactors, process development tools |
| 7 | CRISPR Therapeutics | crisprtherapeutics.com | Head of Platform Development | CRISPR-Cas9 innovator with allogeneic cell therapy pipeline |
| 8 | MilliporeSigma | millipore.com | Sr. Account Manager, Cell & Gene Therapy | Key supplier of reagents, consumables, and validation services for ATMP manufacturing |
| 9 | Vir Bio | virbio.com | VP, Gene Editing Programs | Focus on viral immune evasion and gene-editing approaches for infectious diseases and cancer |
| 10 | ATLAS Ecosystems | atlas-ecosystems.com | CEO | Cell therapy-focused incubator and infrastructure provider |
| 11 | Regeneron Pharmaceuticals | regeneron.com | Director, Gene Therapy Research | Expanding into gene-editing platforms for ocular and genetic diseases |
| 12 | Sartorius AG | sartorius.com | Application Specialist, Cell Culture | Manufacturing equipment and single-use systems for cell therapy production |
| 13 | Spark Therapeutics | sparktherapeutics.com | Chief Scientific Officer | Pioneer in gene therapy with approved Luxturna product |
| 14 | Bio-Techne | biotek.com | Market Development Manager | Supplies critical cell culture media, growth factors, and analytical tools |
| 15 | FDA Office of Cell, Gene and Tissue Therapies | fda.gov | Regulatory Review Officer | Key regulatory body shaping U.S. policy for advanced therapies |
Top 5 Prioritized Samples: Moderna, Roche, Lonza, Bluebird Bio, CRISPR Therapeutics. These represent a cross-section of therapeutic focus areas (mRNA, gene editing, platform development) and industry functions (R&D, manufacturing, regulation).
5. Job Profiles, Industries & Event Type
Best Job Profiles to Target:
- Chief Scientific Officer (CSO)
- VP, Cell & Gene Therapy Development
- Director, Advanced Therapies Manufacturing
- Principal Investigator, Gene Editing
- Head of Regulatory Affairs, ATMP
- Business Development Manager, Cell Therapy Platforms
- Senior Scientist, Vector Development
- Global Marketing Director, Gene Therapy
- Chief Medical Officer (CMO)
- Quality Assurance Director, GMP Compliance
Key Industries (Apollo Industry Filters):
- Biotechnology
- Pharmaceuticals
- Medical Research
- Healthcare
- Life Sciences
- Biomedical Engineering
- Regulatory Affairs
- Contract Manufacturing
- Medical Devices (for therapeutic delivery systems)
6. Estimated Attendance & Footfall
Total Expected Attendance: 4,500+ registered attendees
Breakdown:
- 2,200+ industry professionals (50%)
- 1,000+ researchers and clinicians (22%)
- 700+ investors and service providers (15%)
- 300+ regulatory and academic representatives (7%)
- 200+ exhibitor personnel
Exhibitor Numbers: 200+ companies showcasing technologies, services, and pipeline assets.
7. Key Focus Areas & Buyer Engagement
Core Themes:
- CRISPR and gene-editing technologies
- Allogeneic cell therapy platforms
- Manufacturing scalability and automation
- Regulatory pathways for ATMPs
- Personalized medicine and patient-specific therapies
- Viral vector production innovations
- Cell therapy supply chain logistics
- Commercialization strategies for gene therapies
Buyer Engagement Angle: Position your offering as a solution to manufacturing challenges, regulatory compliance needs, or R&D acceleration tools. Emphasize scalability, cost-efficiency, or novel platforms that address current bottlenecks in cell and gene therapy development.
8. Client-Product Fit Note
To refine the buyer list, please share your client's website and product details. This will help identify whether the focus should be on:
- Manufacturing equipment suppliers (e.g., bioreactors, single-use systems)
- Raw material providers (media, vectors, reagents)
- Regulatory consulting firms (guidance on FDA/EMA submissions)
- Contract research organizations (CROs) (clinical trial support)
- Digital platforms (data analytics, patient registries)
- Logistics providers (temperature-controlled shipping, supply chain tech)
9. Final Recommendation
Quality Rating for B2B Attendee List Sales: 9/10
CGTWC 2026 offers high-value targets across the cell and gene therapy ecosystem. The event's technical depth and executive attendance make it ideal for B2B outreach, particularly for companies offering:
- Manufacturing solutions (CMO/CRO services, equipment)
- Enabling technologies (gene editing, delivery vectors)
- Regulatory and compliance services
- Investment capital or partnership opportunities
Cautions: Ensure strict filtering to exclude academic researchers without procurement authority. Focus on titles with "Therapy," "Manufacturing," "Platform," or "Business Development" in job descriptions.
Data sheet
2nd Edition of Cell & Gene Therapy Conference (CGTWC 2026) – Event Attendee & Buyer Profile Analysis
| Event date | 21 September 2026 – 23 September 2026 | Location | Hilton Garden Inn Miami Dolphin Mall, Miami, Florida, USA |
| Event status | Upcoming | Research date | 30 June 2026 |
Event Overview
| Event Name | 2nd Edition of Cell & Gene Therapy Conference (CGTWC 2026) |
| Event Date | 21 September 2026 – 23 September 2026 |
| Event Status | Upcoming |
| Venue | Hilton Garden Inn Miami Dolphin Mall |
| City | Miami |
| State / Region | Florida |
| Country | USA |
| Organizer | Organizer name not publicly confirmed in the supplied data. |
| Official Event Website | Official event website not provided in the supplied data. |
| Event Type | Scientific conference / biotechnology and life sciences business event |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Business Services |
| Audience Reach | Likely national with international scientific and biopharma relevance |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low at this stage. No official attendee, exhibitor, buyer, or speaker counts were provided in verifiable organizer material within the supplied data. |
| Main Purpose of Event | To convene cell and gene therapy stakeholders across research, clinical development, manufacturing, regulation, investment, and commercialization for partnership building, education, supplier discovery, and market development. |
About the Event
The 2nd Edition of Cell & Gene Therapy Conference (CGTWC 2026) is positioned as a specialized life sciences conference focused on the commercial and scientific ecosystem surrounding cell therapy, gene therapy, translational research, manufacturing readiness, clinical advancement, and regulatory alignment. Based on the supplied event details, the meeting is scheduled for 21–23 September 2026 in Miami, Florida at Hilton Garden Inn Miami Dolphin Mall.
For suppliers, service providers, and business development teams, this type of event typically matters because it brings together decision-makers from biopharma, hospitals, research institutes, CDMOs/CMOs, equipment vendors, regulatory stakeholders, and investors. It is most relevant for B2B outreach tied to R&D tools, process development, GMP manufacturing support, clinical operations, quality and compliance, cold chain, analytics, software, and partnership-led growth. Current-year participant detail remains limited in the supplied data, so this report distinguishes between confirmed facts and likely attendee profiles.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Biopharma R&D leaders | Cell therapy, gene therapy, and advanced biologics developers | Influence platform selection, analytics, assay tools, process development, and strategic partnerships | High relevance for research tools, vectors, software, automation, and specialized scientific services |
| Clinical development and translational medicine teams | Sponsors, hospitals, academic medical centers, investigator networks | Evaluate trial support, patient logistics, data systems, biomarker support, and external labs | Strong relevance for CRO services, patient operations, biospecimen handling, and data platforms |
| Manufacturing and CMC leaders | Biopharma manufacturing groups, CDMOs, process development organizations | Select GMP materials, single-use technologies, fill-finish support, QC systems, and automation vendors | Very strong for manufacturing technology, cleanroom services, QA/QC, and supply chain vendors |
| Regulatory, quality, and compliance teams | Biotech companies, CDMOs, clinical sponsors, consulting firms | Influence validation, documentation systems, eQMS, audit support, and regulatory consulting purchases | High relevance for compliance software, consulting, validation, and regulatory documentation support |
| Procurement and sourcing teams | Biopharma manufacturers, hospitals, academic labs, therapy developers | Own vendor evaluation, supplier onboarding, contract terms, and purchasing workflows | Important for converting conference interest into approved vendor relationships |
| Supply chain and cold-chain logistics leaders | Therapy developers, logistics partners, hospital networks, specialty distributors | Assess chain-of-identity, chain-of-custody, cryogenic shipping, and time-critical fulfillment solutions | High for specialty logistics, packaging, monitoring, and software providers |
| Hospital and treatment center operations leaders | Academic hospitals, cancer centers, specialty treatment sites | Influence site readiness, apheresis support, lab workflows, and administration infrastructure | Relevant for equipment, software, training, and patient workflow support |
| Technology and digital transformation leaders | Biotech, CDMO, health system, and research organizations | Influence LIMS, MES, data integrity, cybersecurity, and integration choices | Strong for life-science software, data platforms, and secure collaboration systems |
| Investors and strategic partners | Venture firms, strategic pharma investors, corporate development groups | Shape partnerships, commercialization paths, and follow-on supplier introductions | Useful for high-value alliance building rather than volume lead generation |
| Scientific advisors, consultants, and association stakeholders | Industry consultants, KOLs, professional groups, ecosystem intermediaries | Influence vendor shortlists and partnership introductions | Good for referral-led pipeline and credibility building |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Miami | Local and fly-in attendees using Miami as an accessible meeting hub | Moderate for regional health systems, distributors, investors, and event-based meetings | Miami supports domestic and Latin America connectivity, which can increase partnership interest for international visitors. |
| Host state: Florida | Florida biotech, healthcare, research, and hospital stakeholders | Moderate | Useful for outreach to Southeast U.S. life sciences and provider networks. |
| Nearby business hubs | South Florida, Tampa Bay, Orlando, Jacksonville, Research Triangle, Boston, New Jersey, Philadelphia | High in established U.S. biotech corridors | These hubs are logical sources of biotech, manufacturing, and investor participation, though current-year attendee origin is not officially published in the supplied data. |
| National reach | Likely U.S.-wide attendance from biotech, pharma, hospitals, CDMOs, and research institutions | High | National scientific conferences in this category generally draw multi-state attendance even when hosted in hotel venues. |
| International reach | Likely selective international participation from Canada, Europe, and Latin America | Medium | International reach is plausible for this therapy area, but not confirmed by organizer-published country data. |
| Trade / partnership corridors | U.S. biotech clusters, academic medical centers, therapy manufacturing sites, cross-border research partnerships | High for strategic B2B introductions | Most valuable for partnership and enterprise-targeted outreach rather than mass-market lead capture. |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| National | Primary classification | Based on the U.S. location, specialized therapy focus, and likely draw from multiple domestic biotech and healthcare hubs. |
| Global | Secondary relevance | The sector itself is global, but current-year international attendance scale is not publicly confirmed in the supplied information. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Current-year buyer organization list not publicly released | Data availability note | No official current-year attendee, buyer, sponsor, exhibitor, or speaker organization list was supplied for verification. | N/A | N/A | Confirmed data unavailable |
| Recommendation | Next-step research action | Use official agenda, speakers page, sponsors page, exhibitor prospectus, or registration partner list once published to build a validated target account set. | N/A | Procurement, CMC, operations, QA, clinical, alliance management | Confirmed data unavailable |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | VP Manufacturing / Head of CMC | Manufacturing | VP / Head | Drives manufacturing strategy, vendor selection, process scale-up, and facility readiness. |
| 2 | Director of Process Development | R&D / Process Development | Director | Key evaluator of enabling technologies, analytics, automation, and upstream/downstream support. |
| 3 | Director of Procurement | Procurement | Director | Owns supplier approval, sourcing decisions, contract management, and purchasing policy. |
| 4 | Strategic Sourcing Manager | Procurement / Supply Chain | Manager | Core buyer contact for qualified vendor pipeline and budget-backed purchase evaluation. |
| 5 | Supply Chain Director | Supply Chain | Director | Critical for cold chain, time-sensitive delivery, inventory continuity, and risk management. |
| 6 | Director of Quality Assurance | Quality / Compliance | Director | Influences validation, documentation, supplier quality, and audit readiness decisions. |
| 7 | Regulatory Affairs Director | Regulatory Affairs | Director | Shapes compliance purchasing, submission support needs, and governance tooling. |
| 8 | Clinical Operations Director | Clinical Operations | Director | Relevant for site support, patient logistics, data systems, and external service procurement. |
| 9 | Chief Scientific Officer / R&D Head | Executive / Scientific Leadership | C-Level / Head | High strategic influence over platforms, partnerships, and long-term vendor ecosystems. |
| 10 | Business Development Director / Alliance Management Director | Business Development / Partnerships | Director | Key contact for co-development, licensing, service partnerships, and channel expansion. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Biotechnology | Primary fit for therapy developers and platform innovators. | R&D tools, CMC support, GMP services, software, partnerships |
| 2 | Pharmaceuticals | Large and mid-size pharma often evaluate advanced therapy partnerships and manufacturing strategies. | Strategic sourcing, commercialization support, alliance development |
| 3 | Hospital & Health Care | Treatment sites and hospital systems matter for clinical and administration workflows. | Patient operations, site readiness, lab support, logistics |
| 4 | Research | Research institutes and translational centers are common stakeholders. | Instrumentation, reagents, assays, informatics |
| 5 | Medical Devices | Relevant for collection systems, processing tools, monitoring equipment, and treatment infrastructure. | Device-led clinical and manufacturing support |
| 6 | Information Technology & Services | Fits digital platforms for manufacturing execution, data integrity, and collaboration. | LIMS, MES, analytics, workflow automation, compliance systems |
| 7 | Logistics & Supply Chain | Advanced therapies require specialized chain-of-custody and temperature-controlled movement. | Cold chain, packaging, monitoring, transport orchestration |
| 8 | Industrial Automation | Relevant to scale-up, repeatability, quality consistency, and manufacturing efficiency. | Automation hardware, robotics, controls, process optimization |
| 9 | Management Consulting | Regulatory, market access, and commercialization consulting often intersect with these events. | Advisory, due diligence, operating model design |
| 10 | Venture Capital & Private Equity | Investor participation is common in high-growth therapy markets. | Partnership sourcing, diligence, portfolio support |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer. | Unconfirmed | No verified organizer count supplied | The reference description included large attendance claims, but those claims conflict with the known date/venue details and were not treated as verified current-year data. |
| Exhibitor count | Not publicly confirmed | Unconfirmed | No official exhibitor directory supplied | Should be verified from a sponsors or exhibitors page when released. |
| Buyer count | Not publicly confirmed | Unconfirmed | No official buyer registration or hosted buyer detail supplied | This appears to be a conference format rather than a pure hosted-buyer trade show. |
| Speaker count | Not publicly confirmed | Unconfirmed | No official agenda or speakers page supplied | Speaker organizations can later become strong account-based targeting inputs. |
| Sponsor count | Not publicly confirmed | Unconfirmed | No sponsor listing supplied | Important for identifying vendors already investing in the audience. |
| Historical attendance | Historical attendance not verified | Historical / prior-year evidence unavailable | No prior-year official report supplied | Prior-year evidence should be used once official archived pages are available. |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Cell and gene therapy R&D | Platform improvement, assay performance, translational acceleration | Scientific demos, capability briefings, co-development discussions | Reagents, analytics, software, discovery services |
| Manufacturing and scale-up | Robust process design, reproducibility, capacity access | Operations-led meetings, plant-readiness discussions, vendor qualification | CDMO support, automation, single-use systems, QC services |
| Clinical development | Site activation, patient operations, data capture, specimen coordination | Meetings with clinical ops, site networks, and hospital stakeholders | CRO services, patient logistics, digital trial support |
| Regulatory and quality | Documentation integrity, audit readiness, compliance governance | Regulatory roundtables, QA/QC solution selling | eQMS, validation, consulting, submission support |
| Supply chain and cold chain | Temperature control, identity preservation, time-critical delivery | Operational case studies, supply continuity workshops | Cryogenic packaging, monitoring, chain-of-custody software, logistics |
| Data and digital transformation | Integrated systems, traceability, data quality, secure collaboration | IT and operations buyer meetings | LIMS, MES, workflow software, cybersecurity-enabled platforms |
| Investment and partnerships | Pipeline visibility, de-risking, commercialization pathways | BD meetings, investor networking, alliance discussions | Strategic advisory, diligence support, market access enablement |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | The subject matter aligns well with enterprise and specialist buyers in biotech, pharma, hospitals, and therapy manufacturing. |
| Decision-maker availability | Medium to High | Conferences in this niche often attract director-and-above profiles, but current-year agenda confirmation is still pending. |
| Data collection potential | Medium | Good once speaker, sponsor, and exhibitor lists are published; currently limited by incomplete public participant data. |
| Apollo targeting potential | High | The audience maps cleanly into Apollo industries, departments, and seniority filters for account-based prospecting. |
| Geographic targeting potential | High | Can be focused on U.S. biotech corridors with optional expansion into Canada and Western Europe. |
| Best outreach approach | High | Use account-based outreach built around process improvement, compliance, manufacturing scale-up, and partnership outcomes. |
| Overall lead quality | High | Strong fit for specialized B2B solutions, though validation depth depends on future publication of official participant data. |
| Best use case | High | Best suited for targeted enterprise prospecting, meeting-setting, sponsor intelligence, and speaker-account mapping. |
| Limitations / risks | Medium | Current public data is thin. This limits list-building confidence until official organizer assets are published. Suitable for B2B attendee list building only after stronger source validation. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Biotechnology; Pharmaceuticals; Hospital & Health Care; Research; Medical Devices; Information Technology & Services; Logistics & Supply Chain; Industrial Automation; Management Consulting; Venture Capital & Private Equity | Covers the most likely attending buyer-side ecosystem for cell and gene therapy. |
| Departments | Procurement; Supply Chain; Operations; Manufacturing; Research; Clinical; Quality Assurance; Regulatory Affairs; Information Technology; Business Development | Prioritizes functions with budget authority or strategic influence. |
| Seniority | C-Level; VP; Head; Director; Manager | Matches decision-maker and influencer layers common in niche scientific events. |
| Job titles | Head of CMC; VP Manufacturing; Director of Process Development; Director of Procurement; Strategic Sourcing Manager; Supply Chain Director; Director Quality Assurance; Regulatory Affairs Director; Clinical Operations Director; Chief Scientific Officer; Alliance Management Director | Creates a tight buyer and influencer target set. |
| Geography | United States first; then Florida, Massachusetts, California, New Jersey, Pennsylvania, North Carolina, Maryland; optional Canada, United Kingdom, Germany, Switzerland | Focuses on the most relevant cell and gene therapy clusters. |
| Employee size | 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Captures growth-stage biotechs and enterprise-scale pharma or provider organizations. |
| Keywords | cell therapy, gene therapy, CAR-T, viral vector, lentiviral, AAV, GMP, CMC, translational medicine, apheresis, cryogenic logistics, chain of custody, chain of identity, QC, process development | Improves relevance and suppresses broad non-therapy biotech noise. |
| Technologies, if relevant | LIMS; MES; eQMS; ERP; laboratory informatics; cold-chain monitoring | Useful if the seller provides software, digital infrastructure, or integration services. |
| Revenue range, if relevant | Prefer mid-market to enterprise where available; early-stage exceptions for platform biotech accounts | Balances purchasing capacity with innovation adoption. |
| Company type | Public companies; private growth-stage biotechs; academic medical centers; nonprofit research institutes; CDMOs | Captures the full likely buying ecosystem around the event. |
Suggested Apollo Search Logic: Target companies in Biotechnology OR Pharmaceuticals OR Hospital & Health Care OR Research, then layer titles such as ("Head of CMC" OR "VP Manufacturing" OR "Director of Process Development" OR "Director of Procurement" OR "Strategic Sourcing Manager" OR "Supply Chain Director" OR "Director Quality Assurance" OR "Regulatory Affairs Director" OR "Clinical Operations Director" OR "Chief Scientific Officer"). Add keywords including "cell therapy" OR "gene therapy" OR "CAR-T" OR "viral vector" OR "GMP" OR "CMC" OR "chain of custody" to improve event-fit precision.
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| User-supplied event brief | Provided input | Confirmed event name, city, state, country, venue, and dates used in this report. | Medium |
| Hilton official website | Venue / hotel operator source | Venue brand verification for Hilton Garden Inn property network. | High for venue operator identity; not event-specific |
| Miami-Dade County official website | Government source | City/region context for Miami geographic analysis. | High for geographic context; not event-specific |
| Verification note | Research constraint | The supplied reference description included conflicting date and venue information versus the known event details. Those conflicting claims were excluded from confirmed reporting. | High |
| Verification note | Research constraint | No official organizer website, agenda, attendee list, speakers page, sponsor list, or exhibitor directory was supplied for current-year verification. | High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2nd Edition of Cell & Gene Therapy Conference (CGTWC 2026) — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds